DOCSLIB.ORG

The Effect of 17Beta-And 17Alpha-Estradiol on Myelination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of 17Beta-And 17Alpha-Estradiol on Myelination The Effect of 17β- and 17α-Estradiol on Myelination and Remyelination in Cerebellar Slices by Cassandra Joy Belo A thesis submitted in conformity with the requirements for the degree of Master of Science Laboratory Medicine and Pathobiology University of Toronto © Copyright by Cassandra Joy Belo 2013 The Effect of 17β- and 17α-Estradiol on Myelination and Remyelination in Cerebellar Slices Cassandra Joy Belo Master of Science Laboratory Medicine and Pathobiology University of Toronto 2013 Abstract Multiple sclerosis is thought to be an autoimmune disease that causes lesions and demyelination of axons in the central nervous system. A reduction in relapses is seen in the third trimester of pregnancy when estrogen levels are highest, followed by an increase in relapses in the first three months post-partum when estrogen levels drop. This thesis focuses on the effect of 17beta- and 17alpha-estradiol on myelination and remyelination in cultured rat cerebellar slices. No reproducible effect of 17beta-estradiol on myelination was detected. However, during lysolecithin-induced demyelination it had a possible protective effect in males and females, although it was not statistically significant. During myelination, 100 nM 17alpha- estradiol caused a small but significant decrease in MBP expression in females. During lysolecithin- induced demyelination, it had a possible, but not statistically significant, protective effect in males. Neither 17beta- nor 17alpha-estradiol had a reproducible or significant effect on remyelination in males or females. ii Acknowledgments I would firstly like to thank Dr. Joan Boggs for taking me on as her final graduate student. Your guidance has made me a better writer and scientist. I would also like to thank the members of the Boggs’ lab, Yuanfang Liu, Godha Rangaraj and Lopamudra Homchaudhuri who have helped me by answering my questions, talking through experiments, listening to all of my presentations and being excellent colleagues to enjoy lunch with. I would also like to thank my friends and family for supporting me through my research. My grandparents for their constant interest in how my research was going and for giving me practice talking about my work. Thank you to Chris for being so understanding and letting me put my research first and knowing when I needed a break. iii Table of Contents Acknowledgments .......................................................................................................................... iii Table of Contents ........................................................................................................................... iv List of Tables ................................................................................................................................ vii List of Figures .............................................................................................................................. viii Abbreviations ................................................................................................................................. ix Chapter 1 Introduction .................................................................................................................... 1 1.1 Multiple Sclerosis ............................................................................................................... 1 1.2 Hormones and MS .............................................................................................................. 3 1.3 Hormone Concentrations .................................................................................................... 6 1.4 Hormone synthesis ............................................................................................................ 10 1.5 Estrogen and Progesterone Receptors ............................................................................... 12 1.6 Myelination and Remyelination ........................................................................................ 14 1.7 Effects of Estrogens .......................................................................................................... 18 1.7.1 Immune System .................................................................................................... 18 1.7.2 CNS Cultured Cells ............................................................................................... 19 1.7.3 CNS Co-cultures and Brain Slices ........................................................................ 22 1.7.4 Animal Trials ........................................................................................................ 23 1.7.5 Clinical Trials ........................................................................................................ 26 1.8 Hypothesis ......................................................................................................................... 27 1.9 Experimental Approach .................................................................................................... 27 Chapter 2 Materials and Methods ................................................................................................. 32 2.1 Slice culture ...................................................................................................................... 32 2.2 Remyelination in slices ..................................................................................................... 32 2.3 Chemicals and Antibodies ................................................................................................ 33 iv 2.4 Western Blotting ............................................................................................................... 33 2.5 Immunohistochemistry ..................................................................................................... 34 2.6 Image Analysis .................................................................................................................. 35 2.7 Statistical Analysis ............................................................................................................ 35 Chapter 3 Results .......................................................................................................................... 36 3.1 Optimization of brain slice culture conditions .................................................................. 36 3.2 Effect of estrogens and progesterone on myelination ....................................................... 38 3.2.1 Effect of 17β-estradiol on myelination in cerebellar brain slices ......................... 39 3.2.2 Effect of 17β-estradiol and progesterone in cerebellar brain slices ...................... 47 3.2.3 Effect of 17α-estradiol on myelination in cerebellar brain slices ......................... 49 3.3 Effect of estrogens on remyelination after lysolecithin demyelination ............................ 53 3.3.1 Optimization of demyelination and remyelination conditions .............................. 53 3.3.2 Effect of 17β-estradiol after lysolecithin treatment on remyelination .................. 56 3.3.3 Effect of 17α-estradiol after lysolecithin treatment on remyelination .................. 59 Chapter 4 Discussion .................................................................................................................... 63 4.1 Quantifying myelination and remyelination ..................................................................... 65 4.2 Effect of estradiol and progesterone on myelination in cerebellar brain slices ................ 65 4.2.1 Effect of 17β-estradiol on myelination ................................................................. 65 4.2.2 Effect of 17α-estradiol on myelination ................................................................. 66 4.2.3 Effect of combined treatment with 17β-estradiol and progesterone on myelination ........................................................................................................... 67 4.3 Effect of estradiol treatment on remyelination in cerebellar brain slices ......................... 69 4.3.1 Effect of 17β-estradiol on demyelination and remyelination ............................... 70 4.3.2 Effect of 17α-estradiol on demyelination and remyelination ............................... 72 4.3.3 Immunohistochemistry analysis of demyelination and remyelination ................. 72 4.4 Myelination versus remyelination ..................................................................................... 74 v 4.5 Influence of ethanol .......................................................................................................... 74 4.6 Advantages and disadvantages of cerebellar brain slices ................................................. 76 4.7 Variations in trials and western blotting ........................................................................... 77 4.8 Variations in immunohistochemistry ................................................................................ 79 4.9 Conclusions ....................................................................................................................... 80 4.10 Future directions ............................................................................................................... 81 References ..................................................................................................................................... 83 vi List of Tables Table 1………………………………………………………………………………………..…...8 Table 2…………………………………………………………………………………………...33 vii List of Figures Figure 1: Four clinical subtypes
Load more

Recommended publications
  • Pharmacological Activation of Estrogen Receptors-Α and -Β Differentially Modulates Keratinocyte Differentiation with Functional Impact on Wound Healing
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 37: 21-28, 2016 Pharmacological activation of estrogen receptors-α and -β differentially modulates keratinocyte differentiation with functional impact on wound healing VLASTA PERŽEĽOVÁ1,2*, FRANTIŠEK SABOL3*, TOMÁŠ VASILENKO4,5, MARTIN NOVOTNÝ5,6, IVAN KOVÁČ5,7, MARTIN SLEZÁK5, JÁN ĎURKÁČ5, MARTIN HOLLÝ5, MARTINA PILÁTOVÁ2, PAVOL SZABO8, LENKA VARINSKÁ1, ZUZANA ČRIEPOKOVÁ2, TOMÁŠ KUČERA9, HERBERT KALTNER10, SABINE ANDRÉ10, HANS-JOACHIM GABIUS10, PAVEL MUČAJI11, KAREL SMETANA Jr8 and PETER GÁL1,5,8,11 1Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University; 2Department of Pathological Anatomy and Physiology, University of Veterinary Medicine and Pharmacy; 3Department of Heart Surgery, East-Slovak Institute of Cardiovascular Diseases and Pavol Jozef Šafárik University; 4Department of Surgery, Košice-Šaca Hospital and Pavol Jozef Šafárik University; 5Department for Biomedical Research, East-Slovak Institute of Cardiovascular Diseases; 6Department of Pathological Physiology, Faculty of Medicine, Pavol Jozef Šafárik University; 72nd Department of Surgery, Louis Pasteur University Hospital and Pavol Jozef Šarfárik University, Košice, Slovak Republic; Institutes of 8Anatomy and 9Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic; 10Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University Munich, Munich, Germany; 11Department of Pharmacognosy and Botany, Faculty of Pharmacy, Comenius University,
    [Show full text]
  • Estrogen Receptor Beta Is a Negative Regulator of Mammary Cell Proliferation Xiaozheng Song University of Vermont
    University of Vermont ScholarWorks @ UVM Graduate College Dissertations and Theses Dissertations and Theses 2014 Estrogen Receptor Beta Is A Negative Regulator Of Mammary Cell Proliferation Xiaozheng Song University of Vermont Follow this and additional works at: https://scholarworks.uvm.edu/graddis Part of the Animal Sciences Commons, and the Molecular Biology Commons Recommended Citation Song, Xiaozheng, "Estrogen Receptor Beta Is A Negative Regulator Of Mammary Cell Proliferation" (2014). Graduate College Dissertations and Theses. 259. https://scholarworks.uvm.edu/graddis/259 This Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact [email protected]. ESTROGEN RECEPTOR BETA IS A NEGATIVE REGULATOR OF MAMMARY CELL PROLIFERATION A Dissertation Presented by Xiaozheng Song to The Faculty of the Graduate College of The University of Vermont In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Specializing in Animal Science October, 2014 Accepted by the Faculty of the Graduate College, The University of Vermont, in partial fulfillment of the requirements for the degree of Doctor of Philosophy, specializing in Animal Science. Dissertation Examination Committee: ____________________________________ Advisor Zhongzong Pan Ph.D. ____________________________________ Co-Advisor Andre-Denis Wright Ph.D. ____________________________________ Rona Delay, Ph.D. ____________________________________ David Kerr, Ph.D. ____________________________________ Chairperson Karen M. Lounsbury, Ph. D. ____________________________________ Dean, Graduate College Cynthia J. Forehand, Ph.D. Date: May 5, 2014 ABSTRACT The mammary gland cell growth and differentiation are under the control of both systemic hormones and locally produced growth factors.
    [Show full text]
  • Modulation of Responses to Stress by Estradiol Benzoate and Selective Estrogen Receptor Agonists
    253 Modulation of responses to stress by estradiol benzoate and selective estrogen receptor agonists Lidia I Serova, Heather A Harris1, Shreekrishna Maharjan and Esther L Sabban Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York 10595, USA 1Women’s Health and Musculoskeletal Biology, Wyeth Research, Collegeville, Pennsylvania 19426, USA (Correspondence should be addressed to E L Sabban; Email: [email protected]) Abstract Previously,pretreatment with estradiol benzoate (EB) was found IMO, indicating an ERa (ESR1)-, but not ERb (ESR2)-, to modulate the response of hypothalamic–pituitary–adrenal mediated mechanism. In the locus coeruleus (LC), the rise in (HPA) axis and gene expression in several catecholaminergic dopamine-b-hydroxylase (Dbh) mRNA with both stress neuronal locations in ovariectomized (OVX) rats exposed to paradigms was abrogated in EB- or PPT-injected animals. single immobilization stress (IMO). Here, we investigated the However, WAY-200070 blocked the response of DBH mRNA role of estrogen receptor (ER) subtypes, using selective agonists to single IMO but not to repeated IMO. In the nucleus of the for ERa (propyl pyrazole triol, PPT) or ERb (WAY-200070) in solitary tract (NTS), the rise in tyrosine hydroxylase and DBH two major central noradrenergic systems and the HPA axis after mRNAs with both IMOs was absent, or greatly attenuated, in exposure to single and repeated IMO.OVX female rats received EB- or PPT-treated rats. In most cases, WAY-200070 inhibited 21 daily injections of either EB (25 mg/kg), PPT (10 mg/kg), the response to single IMO but not to repeated IMO.The results WAY-200070 (10 mg/kg), or vehicle.
    [Show full text]
  • Inhibitory Effect of 17Β‑Estradiol on Triglyceride Synthesis in Skeletal Muscle Cells Is Dependent on ESR1 and Not ESR2
    MOLECULAR MEDICINE REPORTS 19: 5087-5096, 2019 Inhibitory effect of 17β‑estradiol on triglyceride synthesis in skeletal muscle cells is dependent on ESR1 and not ESR2 QUAN LIU1*, RUI LI1*, GUANJUN CHEN2, JIANMING WANG3, BINGFENG HU1, CHAOFEI LI4, XIAOHUAN ZHU5 and YUNXIA LU4,6 1Department of Clinical Pharmacy, Class 2014, School of Pharmacy; 2Center of Scientific Research, Anhui Medical University, Hefei, Anhui 230032; 3Dalian Maple International School, Dalian, Liaoning 116100; 4The Comprehensive Laboratory, Anhui Medical University; 5Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University; 6Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China Received July 13, 2018; Accepted March 13, 2019 DOI: 10.3892/mmr.2019.10189 Abstract. The present study aimed to investigate the inhibitory note, treatment with E2 restored the expression levels of the effects and the mechanisms underlying 17β-estradiol (E2) aforementioned factors. In C2C12 cells, treatment with E2 or effects on triglyceride synthesis and insulin resistance PPT reversed the alterations induced by treatment with PA. In in skeletal muscle tissues and cells. Ovariectomy (OVX) contrast, pretreatment with DPN did not influence the effect was performed on 6-month-old female rats treated with or of PA. Collectively, E2 was able to interact with ESR1, thus without E2. Subsequently, various serum biochemical markers activating the CD36-PPARα pathway, decreasing the level of were measured. Additionally, pathological alterations of TG in the muscles and improving insulin resistance in skeletal the uterus, liver and skeletal muscle were analyzed, and muscles and C2C12 cells. the content of triglycerides (TG) in muscle was detected.
    [Show full text]
  • Estradiol Replacement Therapy Regulates Innate Immune Response
    International Immunopharmacology 72 (2019) 504–510 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Estradiol replacement therapy regulates innate immune response in ovariectomized arthritic mice T ⁎ Ayda Henriques Schneidera,b,1, Alexandre Kanashiroc, ,1, Sabrina Graziani Veloso Dutraa, Raquel do Nascimento de Souzaa, Flávio Protásio Verasb, Fernando de Queiroz Cunhab, ⁎ Luis Ulload, André Souza Mecawia,e, Luis Carlos Reisa, David do Carmo Malvara, a Department of Physiological Sciences, Multicentric Program of Post-Graduation in Physiological Sciences, Federal Rural University of Rio de Janeiro, BR 465/Km 07, 23897-000 Seropédica, RJ, Brazil b Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil c Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, 14049-900 Ribeirao Preto, Brazil d Department of Surgery, Center of Immunology and Inflammation, Rutgers University - New Jersey Medical School, Newark, NJ 07103, USA e Department of Biophysics, Paulista School of Medicine, Federal University of São Paulo, Rua Botucatu, 862, CEP 04023-062 São Paulo, SP, Brazil ARTICLE INFO ABSTRACT Keywords: Neuroendocrine changes are essential factors contributing to the progression and development of rheumatoid Arthritis arthritis. However, the role of estrogen in the innate immunity during arthritis development is still controversial. Estrogen Here, we evaluated the effect of estrous cycle, ovariectomy, estradiol replacement therapy and treatment with fl In ammation estrogen receptor (ER)α and ERβ specific agonists on joint edema formation, neutrophil recruitment, and ar- Neutrophil ticular levels of cytokines/chemokines in murine zymosan-induced arthritis.
    [Show full text]
  • Sfn2015 Items of Interest
    Presentations and Posters of Interest Society for Neuroscience Meeting (2015) 34.01/A100. Estradiol rapidly attenuates ORL-1 receptor-mediated inhibition of proopiomelanocortin neurons via Gq-coupled, membrane-initiated signaling *K. M. CONDE1, C. MEZA2, M. KELLY3, K. SINCHAK4, E. WAGNER2; 1Grad. Col. of Biomed. Sci., 2Col. of Osteo. Med. of the Pacific, Western Univ. of Hlth. Sci., Pomona, CA; 3 Dept. of Physiol. & Pharmacol., Oregon Hlth. and Sci. Univ., Portland, OR; 4California State University, Long Beach, Long Beach, CA Ovarian estrogens act through multiple receptor signaling mechanisms that converge on hypothalamic arcuate nucleus (ARH) proopiomelanocortin (POMC) neurons. A subpopulation of these neurons project to the medial preoptic nucleus (MPN) to regulate lordosis. Orphanin FQ/nociception (OFQ/N) via its opioid-like receptor (ORL-1) regulates lordosis through direct actions on these MPN-projecting POMC neurons. Based o an ever-burgeoning precedence for fast steroid actions, we explored whether estradiol excites ARH POMC neurons by rapidly attenuating inhibitory ORL-1 signaling in these cells. Experiments were carried out in hypothalamic slices prepared from ovariectomized female rats injected one-week prior with the retrograde tracer Fluorogold into the MPN. During electrophysiologic recordings, cells were held at or near -60 mV. Post-hoc identification of neuronal phenotype was determined via immunohistofluorescence. In vehicle-treated slices OFQ/N caused a robust outward current/hyperpolarization via activation of GIRK channels. This OFQ/N-induced outward current was attenuated by 17-β estradiol (E2, 100nM). The 17α enantiomer of E2 had n effect. The OFQ/N-induced response was also attenuated by an equimolar concentration of E2 conjugated to BSA.
    [Show full text]
  • G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives
    cells Review G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives Richard A. Pepermans 1, Geetanjali Sharma 1,2 and Eric R. Prossnitz 1,2,3,* 1 Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA; [email protected] (R.A.P.); [email protected] (G.S.) 2 Center of Biomedical Research Excellence in Autophagy, Inflammation and Metabolism, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA 3 University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA * Correspondence: [email protected]; Tel.: +1-505-272-5647 Abstract: Estrogen is involved in numerous physiological and pathophysiological systems. Its role in driving estrogen receptor-expressing breast cancers is well established, but it also has important roles in a number of other cancers, acting both on tumor cells directly as well as in the function of multiple cells of the tumor microenvironment, including fibroblasts, immune cells, and adipocytes, which can greatly impact carcinogenesis. One of its receptors, the G protein-coupled estrogen receptor (GPER), has gained much interest over the last decade in both health and disease. Increasing evidence shows that GPER contributes to clinically observed endocrine therapy resistance in breast cancer while also playing a complex role in a number of other cancers. Recent discoveries regarding the targeting of GPER in combination with immune checkpoint inhibition, particularly in melanoma, have led to the initiation of the first Phase I clinical trial for the GPER-selective agonist G-1.
    [Show full text]
  • Role of Phytoestrogen Ferutinin in Preventing/Recovering Bone Loss: Results from Experimental Ovariectomized Rat Models
    35 Role of Phytoestrogen Ferutinin in Preventing/Recovering Bone Loss: Results from Experimental Ovariectomized Rat Models Carla Palumbo, Francesco Cavani, Laura Bertoni and Marzia Ferretti Department of Biomedical Sciences, Section of Human Morphology, University of Modena and Reggio Emilia Italy 1. Introduction Osteoporosis is a chronic bone disease, caused by an imbalance between bone resorption and bone formation (Riggs & Melton, 1986), in which the skeleton becomes fragile and leads to an increased risk of fractures. In osteoporosis the bone mineral density is rapidly reduced, the bone microarchitecture is disrupted and the amount/variety of non-collagenous bone proteins is altered (Chestnut, 1995; Paschalis et al., 1997). In menopausal women, the rapid decrease of estrogens is the predominant cause of the imbalance between bone formation and bone resorption that results, in turn, in severe bone loss (Riggs & Melton, 1986). Hormone Replacement Therapy (HRT), based on estrogen administration, is a method to recover both bone loss and incidence of skeletal fractures in postmenopausal women (Turner et al., 1994); however, as it is well known, it increases, as negative side effects, the occurrence of cardiovascular diseases and endometrial/breast/ovarian malignant cancers (Beral, 2003; Genant et al., 1998; Lacey et al., 2002; Termine & Wong, 1998). In addition to HRT, other compounds such as bisphosphonates, calcitonin, calcium products, RANK Ligand, stronzium ranelate, PTH 1-34, thiazide diuretics and ipriflavone (Bruhn, 2010; El- Desoky et al., 2009; Lacroix, 2000; Rybchyn et al., 2011; Schoofs, 2003; Wasnich, 1983; Zhang et al., 2010) are currently used as pharmacological approaches to osteoporosis, but they are often associated with negative side effects.
    [Show full text]
  • Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy
    International Journal of Molecular Sciences Review Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy Jin Bai 1 , Qian-Rong Qi 1 , Yan Li 1, Robert Day 1, Josh Makhoul 1 , Ronald R. Magness 2 and Dong-bao Chen 1,* 1 Department of Obstetrics & Gynecology, University of California, Irvine, CA 92697, USA; [email protected] (J.B.); [email protected] (Q.-R.Q.); [email protected] (Y.L.); [email protected] (R.D.); [email protected] (J.M.) 2 Department of Obstetrics & Gynecology, University of South Florida, Tampa, FL 33612, USA; [email protected] * Correspondence: [email protected]; Tel.: +949-824-2409 Received: 27 May 2020; Accepted: 15 June 2020; Published: 18 June 2020 Abstract: Normal pregnancy is associated with dramatic increases in uterine blood flow to facilitate the bidirectional maternal–fetal exchanges of respiratory gases and to provide sole nutrient support for fetal growth and survival. The mechanism(s) underlying pregnancy-associated uterine vasodilation remain incompletely understood, but this is associated with elevated estrogens, which stimulate specific estrogen receptor (ER)-dependent vasodilator production in the uterine artery (UA). The classical ERs (ERα and ERβ) and the plasma-bound G protein-coupled ER (GPR30/GPER) are expressed in UA endothelial cells and smooth muscle cells, mediating the vasodilatory effects of estrogens through genomic and/or nongenomic pathways that are likely epigenetically modified. The activation of these three ERs by estrogens enhances the endothelial production of nitric oxide (NO), which has been shown to play a key role in uterine vasodilation during pregnancy. However, the local blockade of NO biosynthesis only partially attenuates estrogen-induced and pregnancy-associated uterine vasodilation, suggesting that mechanisms other than NO exist to mediate uterine vasodilation.
    [Show full text]
  • Thesis Behavioral Effects Of
    THESIS BEHAVIORAL EFFECTS OF ESTROGEN RECEPTOR BETA ACTING LOCALLY TO REGULATE THE EXPRESSION OF TRYPTOPHAN HYDROXYLASE 2 (TPH2) IN SEROTONERGIC NEURONS OF THE DORSAL RAPHE NUCLEI submitted by Nina Caroline Donner Department of Biomedical Sciences In partial fulfillment of the requirements for the Degree of Master of Science Colorado State University Fort Collins, CO Fall 2008 COLORADO STATE UNIVERSITY November 7, 2008 WE HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER OUR SUPERVISION BY NINA CAROLINE DONNER ENTITELDED: “BEHAVIORAL EFFECTS OF ESTROGEN RECEPTOR BETA ACTING LOCALLY TO REGULATE THE EXPRESSION OF TRYPTOPHAN HYDROXYLASE 2 (TPH2) IN SEROTONERGIC NEURONS OF THE DORSAL RAPHE NUCLEI” BE ACCEPTED AS FULFILLING IN PART REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE. Committee on Graduate Work ________________________________________ (Dr. Ronald Tjalkens) ________________________________________ (Dr. Colin Clay) ________________________________________ (Dr. Stuart Tobet) ________________________________________ Advisor (Dr. Robert Handa) ________________________________________ Department Head/Director ii ABSTRACT OF THESIS BEHAVIORAL EFFECTS OF ESTROGEN RECEPTOR BETA ACTING LOCALLY TO REGULATE THE EXPRESSION OF TRYPTOPHAN HYDROXYLASE 2 (TPH2) IN SEROTONERGIC NEURONS OF THE DORSAL RAPHE NUCLEI Affective disorders often involve serotonin (5-HT)-related dysfunctions and are twice as common in women than men. Interactions between estrogen and the brain 5-HT system have long been proposed to contribute to sex differences in mood and anxiety disorders, but the mechanisms underlying this phenomenon have yet to be revealed. Estrogen signaling is mediated by two different receptors termed estrogen receptor alpha and estrogen receptor beta. While estrogen receptor alpha (ERalpha) has mainly reproductive responsibilities, in brain, estrogen receptor beta (ERbeta) has been shown to attenuate anxiety- and despair-like behaviors in rodent models.
    [Show full text]
  • Nuclear Hormone Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology (2017) 174, S208–S224 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors Stephen PH Alexander1, John A Cidlowski2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5, Simon D Harding5,AdamJPawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA 3School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13880/full. Nuclear hormone receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, catalytic receptors, enzymes and transporters.
    [Show full text]
  • The Concise Guide to PHARMACOLOGY 2015/16: Nuclear Hormone Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. British Journal of Pharmacology (2015) 172, 5956–5978 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Nuclear hormone receptors Stephen PH Alexander1, John A Cidlowski2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and L CGTP Collaborators N 1 School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2 National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA, 3 School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4 Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5 Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13352/full. Nuclear hormone receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]